At the American Society of Clinical Oncology’s 2026 meeting, Pfizer showcased its expanded oncology portfolio, emphasizing integration of Seagen’s targeted therapy assets secured in its $43 billion 2023 acquisition. Management outlined key data readouts and regulatory milestones planned through 2027 for both solid tumor and hematological candidates, signaling potential revenue growth catalysts.